regn10933
mAbexperimentalCOVID-19
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 9, 2020 (NCT04425629)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04666441 | Phase 2 | Dec 15, 2020 | Regeneron |
| NCT04519437 | Phase 1 | Jul 26, 2020 | Regeneron |
| NCT04452318 | Phase 3 | Jul 13, 2020 | Regeneron |
| NCT04426695 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2020 | Regeneron |
| NCT04425629 | Phase 1/Phase 2 (Phase 2) | Jun 9, 2020 | Regeneron |
| NCT04617535 | N/A | — | Regeneron |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 6 | 6 | 4 | 2020 |
1 organizations
Page 1 / 1